Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.

CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2.5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile. PMID: 32479641 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32479641?dopt=Abstract

Source: The British Journal of Dermatology - May 31, 2020 Category: Dermatology Authors: Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA Tags: Br J Dermatol Source Type: research